The NIH-industry new therapeutic uses pilot program: Demonstrating the power of crowdsourcing

Assay and Drug Development Technologies

Volumn 13, Issue 6, 2015, Pages 297-298

  Colvis, Christine M ^a   Austin, Christopher P ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; CROWDSOURCING; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESEARCH; DRUG USE; HUMAN; NATIONAL HEALTH ORGANIZATION; PHARMACEUTICAL CARE; PILOT STUDY; REVIEW; ADVERTISING; FINANCIAL MANAGEMENT; TRANSLATIONAL RESEARCH; TRENDS; UNITED STATES;

ADVERTISING AS TOPIC; CROWDSOURCING; DRUG INDUSTRY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); RESEARCH SUPPORT AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 84938691141     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2015.29006.cmcdrrr     Document Type: Review

References (4)

1. Arcaroli J, Quackenbush K, Dasari A, et al. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer Med. 2012;1:207-217.
2. Kendrew J, Odedra R, Logie A, et al. Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies. Cancer Chemother Pharmacol. 2013;71:1021-1032.
3. Spijkers-Hagelstein JA, Mimoso Pinhancos S, Schneider P, Pieters R, Stam RW. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia. 2013;27:1063-1071.
4. Gangadhar TC, Clark JI, Karrison T, Gajewski TF. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013;31:769-773.